Therapeutic drug monitoring survey of anti-MRSA agents in Japan

Masahiro Kobayashi, Yoshio Takesue, Yusuke Tanigawara, Hiroshige Mikamo, Toshimi Kimura, Sumio Hirata, Tadashi Shiraishi, Toshiyuki Sakaeda, Shunji Takakura

研究成果: Short survey

3 引用 (Scopus)

抜粋

We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.

元の言語English
ページ(範囲)119-124
ページ数6
ジャーナルJapanese Journal of Chemotherapy
58
発行部数2
出版物ステータスPublished - 2010 3 1
外部発表Yes

    フィンガープリント

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

これを引用

Kobayashi, M., Takesue, Y., Tanigawara, Y., Mikamo, H., Kimura, T., Hirata, S., Shiraishi, T., Sakaeda, T., & Takakura, S. (2010). Therapeutic drug monitoring survey of anti-MRSA agents in Japan. Japanese Journal of Chemotherapy, 58(2), 119-124.